# US 2013/0158077 A1 · Pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158077 A1
- Document ID: US20130158077A1
- Status: Published application
- Kind: A1
- Application number: 13/654,632
- Filed: 2012-10-18
- Published: 2013-06-20
- Earliest claimed: 2011-12-19
- Assignees: Ares Trading S.A.
- Inventors: BJOERN C. KAHRS
- Web page: https://patentgrep.com/patent/US20130158077A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/12: Ketones
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/225: Polycarboxylic acids
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 31/426: 1,3-Thiazoles
- A61K 31/47: Quinolines; Isoquinolines
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 5/48: of the pancreatic hormones
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

## Claims

### Claim 1

A method of treating multiple sclerosis or clinically isolated syndrome (CIS) comprising the administration of a pharmaceutical composition comprising a glitazone and a fumaric acid monoalkyl ester and/or fumaric acid dialkyl ester to a patient having multiple sclerosis or clinically isolated syndrome.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the fumaric acid dialkyl ester is selected from dimethyl fumarate or diethyl fumarate and the fumaric acid monoalkyl ester is selected from monomethyl hydrogen fumarate or monoethyl hydrogen fumarate.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the fumaric acid dialkyl ester is dimethyl fumarate.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the glitazone is pioglitazone or rosiglitazone.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said composition comprises a fumaric acid dialkyl ester selected from dimethyl fumarate or diethyl fumarate, the glitazone is pioglitazone or rosiglitazone and said pharmaceutical composition is a solid oral dosage form.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said fumaric acid dialkyl ester is dimethyl fumarate.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said patient has multiple sclerosis.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said patient has clinically isolated syndrome.

### Claim at position 9

9-15. (canceled)

### Claim 16 (depends on 1)

The method according to claim 1, wherein said pharmaceutical composition comprises a glitazone and a fumaric acid monoalkyl ester.

### Claim 17 (depends on 1)

The method according to claim 1, wherein said pharmaceutical composition comprises a glitazone and a fumaric acid dialkyl ester.

### Claim 18 (depends on 1)

The method according to claim 1, wherein said pharmaceutical composition comprises a glitazone, a fumaric acid monoalkyl ester and a fumaric acid dialkyl ester.
